Webdisclosure.com

IMMUNIC, INC.

21/11/2023 12:30

EQS-News: Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis

Voir tous les communiqués de Immunic, Inc.

IMMUNIC, INC.

02/11/2023 11:30

EQS-News: Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts

Voir tous les communiqués de Immunic, Inc.

IMMUNIC, INC.

26/10/2023 12:30

EQS-News: Immunic to Participate in Scientific and Industry Conferences in November

Voir tous les communiqués de Immunic, Inc.

IMMUNIC, INC.

16/10/2023 12:30

EQS-News: Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023

Voir tous les communiqués de Immunic, Inc.

IMMUNIC, INC.

15/10/2023 12:30

EQS-News: Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

Voir tous les communiqués de Immunic, Inc.

IMMUNIC, INC.

11/10/2023 12:30

EQS-News: Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting

Voir tous les communiqués de Immunic, Inc.

IMMUNIC, INC.

09/10/2023 22:01

EQS-News: Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

Voir tous les communiqués de Immunic, Inc.

IMMUNIC, INC.

04/10/2023 12:30

EQS-News: Immunic to Participate in Scientific Conferences in October

Voir tous les communiqués de Immunic, Inc.

IMMUNIC, INC.

06/09/2023 12:30

EQS-News: Immunic to Participate in Industry and Investor Conferences in September

Voir tous les communiqués de Immunic, Inc.

IMMUNIC, INC.

17/08/2023 12:30

EQS-News: Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

Voir tous les communiqués de Immunic, Inc.

1
2
3
4
5
6
7
8
9
10